For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
#1 (Strong Buy) stocks have produced an unmatched +23.94% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: The Cooper Companies (COO - Free Report) The Cooper Companies is a global medical device company operating through two main segments: CooperVision (CVI) and CooperSurgical (CSI). CVI focuses on contact lenses, with a strong presence in daily silicone hydrogel lenses, torics, multifocals, and myopia management. Its flagship MyDay franchise, including MyDay Energys and toric/multifocal expansions, continues to capture premium share, while MiSight addresses the growing myopia epidemic. CSI provides products and services in fertility and women’s health, offering in-vitro fertilization (IVF) solutions, contraceptives such as Paragard, and office/surgical devices.
COO is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 15.45; value investors should take notice.
Five analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.02 to $4.63 per share. COO boasts an average earnings surprise of +5.8%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, COO should be on investors' short list.
Jason Kidd is the chief operating officer at Chipotle. Chipotle Chipotle chief operating officer Jason Kidd visits roughly a dozen Chipotle stores every week — and said he's always on the hunt for talent.
At the end of each day, Kidd told Business Insider he sits down for a roughly 90-minute dinner with three or four members of the regional team in the market he's visiting.
He said these meals help strengthen day-to-day operations and offer him a chance to get to know employees. It also gives him an opportunity to scan for internal promotions.
"We're constantly identifying internal talent during these visits, seeing how people show up and see how they react," said Kidd. Last year, Chipotle promoted 23,000 workers.
As of March of this year, the restaurant chain had over 4,100 locations globally and employed over 135,000 people. All of the company's regional vice president promotions last year were internal, Kidd said. The company plans to open up to 370 new restaurants this year.
Those dinners provide a chance to "get to know people in a different way," said Kidd, who joined Chipotle last year, after serving as COO at Taco Bell.
Specifically, the dinners are a chance to learn more about employees — what they want to do and whether they're interested in advancing their careers. When he's considering someone for a promotion, he said he's looking for four key qualities.
The first is people who take care of one another and work well in groups.
"At the end of the day, we run a people business," Kidd said. "So you need to make sure you take care of your people."
As workers climb the leadership ladder, Kidd said, collaboration becomes increasingly important, along with building both personal and professional connections.
The second quality he looks for is people who "own the outcome."
When he asks them how things are going, they take responsibility — whether the news is good or bad — and give him an honest assessment.
"They know how to deliver results," Kidd said, adding that "if somebody can own the outcome of what they're doing, they're likely going to be a good leader."
The third trait is the ability to anticipate problems instead of simply reacting to them.
"We don't need firefighters; we need people who could be ahead of the issues and anticipate what's going on," he said.
The fourth quality is strong problem-solving skills. In the restaurant business, plenty can go wrong. Kidd said he's looking for leaders who don't just flag issues — anyone can identify a problem — but also come up with solutions.
Read next
Ana Altchek You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.
On July 02, 2026, The Cooper Companies Inc (COO) shares rose 3.1% today, bringing the current price to $74.20. The stock has experienced a 52-week range of $58.
Charlie Nelson appointed Chairman and CEO; Ted Warner named President, CFO and appointed to Board; José Rodriguez appointed COO Charlie Nelson appointed Chairman and CEO; Ted Warner named President, CFO and appointed to Board; José Rodriguez appointed COO
SAN RAMON, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, released today its 2025 Corporate Sustainability Report. The report showcases the company’s commitment to people and planet, supported by expanded performance metrics and continued progress on sustainability priorities. A key milestone in this year’s report is the company’s first-time disclosure of Scope 3 greenhouse gas emissions, enhancing transparency and strengthening its sustainability reporting.
“These achievements are the direct result of our global team’s partnership, innovation, and dedication to the customers and patients we serve,” said Al White, CooperCompanies President and CEO.
In 2025, CooperCompanies accelerated innovation across its portfolio, introducing impactful solutions that elevate standards in vision care and women’s health and fertility while advancing its sustainability performance.
At CooperVision, the launch of the MADE BETTER™ platform reinforced the company’s commitment to responsible material sourcing, waste reduction, and minimizing environmental impact. CooperSurgical advanced reproductive health and medical technology with innovative solutions including the launch of ViaBL™ Super-Fast Blastocyst Warming Kit, designed to simplify and accelerate blastocyst warming, and a renewable cooler made from 85% renewable plant-based fibers for IVF shipments.
These advancements were supported by robust scientific leadership across both CooperVision and CooperSurgical, with 69 peer-reviewed posters and presentations showcased at leading global conferences.
The 2025 Sustainability Report aligns with multiple leading sustainability frameworks, including continued adherence to the SASB Standards and, for the first time, alignment with the Task Force on Climate-related Financial Disclosures (TCFD), reflecting the company’s commitment to best-practice sustainability reporting.
Read more in the CooperCompanies 2025 Corporate Sustainability Report.
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life’s beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women’s healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com.
Forward-Looking Statements
This press release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to the Company’s efforts to enhance long-term shareholder value, plans, strategies, future actions, and other statements of which are other than statements of historical fact, are forward-looking. Forward-looking statements necessarily depend on assumptions, data, or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Statements regarding future events and performance and contain words such as “expects” and similar words or phrases. A wide range of factors could materially affect future developments, including, but not limited to, uncertainties related to market conditions and other factors set forth in our other filings with the United States Securities and Exchange Commission, including our most recent Annual Report on Form 10-K. These risks and uncertainties may cause actual future results or actions to be materially different than those expressed in such forward-looking statements. We do not intend, or undertake any duty, to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contact:
Kim Duncan
Vice President, Investor Relations and Risk Management
925-460-3663 [email protected]
Key Takeaways COO's two healthcare platforms span contact lenses and fertility, reducing reliance on one end market.MyDay and MiSight drove premium growth, with MiSight revenue up 24% to $32M in fiscal Q2.Asia-Pacific softness, hydrogel exits and margin pressures keep COO's investment case measured. The Cooper Companies, Inc. (COO - Free Report) has two durable healthcare platforms, but its investment case is being shaped by execution as much as demand.
Premium contact lenses, myopia control and fertility products support growth. Asia-Pacific softness, legacy product exits and cost pressure keep the outlook measured.
Why COO’s Two-Segment Model MattersCooperVision gives COO scale in contact lenses, a category with recurring demand once patients are fitted and reorder lenses. For fiscal 2025, CooperVision generated $2.74 billion, or 67% of net sales.
CooperSurgical adds fertility, office and surgical products, reducing reliance on one end market. Its fiscal 2025 revenues were $1.35 billion, or 33% of net sales, giving COO a second healthcare growth engine.
Sales are expected to grow by more than 5% in fiscal 2026 as well as in fiscal 2027.
Image Source: Zacks Investment Research
How CooperVision Drives Premium MixThe main mix story is the migration from lower-value clariti lenses to MyDay daily silicone hydrogel lenses. MyDay delivered double-digit growth in the second quarter of fiscal 2026, while daily silicone hydrogel lenses grew 8%.
Toric and multifocal revenues rose 7% organically, supported by MyDay Energys, multifocal lenses, trial activity, practitioner engagement and broader parameter availability. Alcon Inc. (ALC - Free Report) is a relevant peer because its vision-care portfolio also includes contact lenses and ocular health, keeping competitive focus on product breadth.
Why MiSight Keeps Cooper RelevantMiSight gives CooperVision a differentiated position in pediatric myopia control, not just another lens extension. The product is the only FDA-approved daily contact lens to slow myopia progression in children.
In the second quarter of fiscal 2026, MiSight revenue grew 24% to $32 million. Japan momentum exceeded expectations, while MyDay MiSight in Europe performed well with eye-care practitioners, reinforcing a premium, clinically driven category.
COO’s Pressure PointsAsia-Pacific remains the clearest near-term drag. CooperVision’s Asia-Pacific revenue declined 6% organically to $130.6 million in the second quarter of fiscal 2026, with weakness tied to China, Japan and Korea.
The hydrogel rationalization program could pressure results into 2027. Gross margin also faces tariffs, freight, foreign exchange and lower production, with management expecting third-quarter gross margin of about 66%.
Despite the gross margin facing macro headwinds, COO’s earnings per share is estimated to improve 12.4% in fiscal 2026.
Image Source: Zacks Investment Research
How CooperSurgical Broadens the StoryCooperSurgical keeps the total thesis from depending only on vision care. In the second quarter of fiscal 2026, CSI revenue was $358 million, up 6% organically, with fertility revenue of $143.8 million rising 10% organically.
Paragard performed better than expected with flat revenue growth, while office and surgical products added stability. Bausch + Lomb Corporation (BLCO - Free Report) offers another eye-health comparison point, but COO’s fertility exposure gives it a different diversification profile.
How COO’s Rating Signals Fit the StoryThe bottom line is balanced. COO has attractive category exposure, premium product momentum and cash generation, but regional resets, litigation payouts and margin headwinds keep the investment case measured.
The stock currently carries a Zacks Rank #3 (Hold), which aligns with the Neutral recommendation. That rank points to a more wait-and-see setup rather than a clear near-term earnings revision signal. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
COO’s Style Scores are more constructive, with a VGM Score of B, Value Score of B and Growth Score of B. These scores support the view that the stock has reasonable valuation and growth characteristics. However, the Momentum Score of D suggests weaker timing support, making execution in Asia-Pacific, margin recovery and cash conversion key watch points.
Shannon Lucas, President & Chief Operating Officer of Slide Insurance Holdings (SLDE 0.10%), reported the sale of 18,279 indirectly-held shares valued at approximately $343,000 on May 20, 2026, according to a SEC Form 4 filing.
Transaction summaryMetricValueShares sold (indirect)18,279Transaction value$343,000Post-transaction shares (direct)220,000Post-transaction shares (indirect)41,137,814Post-transaction value (direct ownership)~$4.11 millionTransaction value based on SEC Form 4 weighted average reported price ($18.78); post-transaction value based on May 20, 2026 market close.
Key questionsWhat does the relatively small percentage of holdings traded in this transaction indicate?
The 0.04% of total holdings sold suggests this filing reflects a minor portfolio adjustment, especially when compared to the larger volume of shares disposed in recent months.How was the sale executed and through which entity?
The sale was conducted indirectly through Securus Risk Management LLC, an entity controlled by Shannon Lucas, with no direct holdings affected by this transaction.How does this trade fit within the recent cadence of insider selling?
Following a series of larger indirect sales since March, this smaller sale aligns with the pattern of declining trade sizes as the available indirect share capacity has diminished.How does the transaction value compare to the company's current market capitalization?
The ~$343,000 transaction represents a negligible fraction of Slide Insurance Holdings' $2.13 billion market capitalization as of May 24, 2026, indicating no material impact on float or insider alignment.Company overviewMetricValueRevenue (TTM)$1.26 billionNet income (TTM)$490.98 millionEmployees3921-year price change-8.00%* 1-year price change calculated as of May 20, 2026.
Company snapshotSlide Insurance offers property and casualty insurance products, focusing on underwriting single family and condominium policies.It generates revenue primarily through insurance premiums, leveraging risk assessment and underwriting expertise to manage claims and profitability.The company targets homeowners and condominium owners in the U.S., with headquarters in Tampa, Florida.Slide Insurance Holdings operates as a specialized property and casualty insurance provider, emphasizing efficient underwriting and risk management. The company leverages a focused business model to serve residential property owners, with a notable presence in high-demand regions. Its scale and profitability are supported by disciplined operations and a targeted approach to customer acquisition.
What this transaction means for investorsThe May 20 sale of Slide Insurance stock by COO Shannon Lucas came at a time when shares had rebounded from a 52-week low of $12.53 reached in September. In fact, she made additional dispositions after this one.
Even so, her sales are not a cause for investor concern. This was a non-discretionary transaction as part of a pre-arranged Rule 10b5-1 trading plan adopted in November of 2025. Such plans are often implemented by insiders to avoid accusations of trading based on insider information.
Moreover, Lucas maintained a substantial equity stake post-transaction, thanks primarily to the holdings of her husband, Bruce Lucas, Slide’s CEO. Consequently, her sales are not a red flag.
Slide Insurance is doing well. In the first quarter, revenue increased 38% year over year to $389.3 million, and gross premiums written grew 49%. In May, the company announced it was expanding into California, which has seen a significant exodus of insurance companies due to the state’s rules requiring insurance businesses to pay into a state-funded insurance program and to get government approval for rate increases. The expansion could add to the company’s growing revenue.
Robert Izquierdo has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: The Cooper Companies (COO - Free Report) The Cooper Companies is a global medical device company operating through two main segments: CooperVision (CVI) and CooperSurgical (CSI). CVI focuses on contact lenses, with a strong presence in daily silicone hydrogel lenses, torics, multifocals, and myopia management. Its flagship MyDay franchise, including MyDay Energys and toric/multifocal expansions, continues to capture premium share, while MiSight addresses the growing myopia epidemic. CSI provides products and services in fertility and women’s health, offering in-vitro fertilization (IVF) solutions, contraceptives such as Paragard, and office/surgical devices.
COO is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 15.41; value investors should take notice.
Four analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.01 to $4.63 per share. COO boasts an average earnings surprise of +5.8%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, COO should be on investors' short list.
COO's premium lenses, MiSight and fertility trends support growth, but Asia-Pacific softness, portfolio shifts and cost pressure keep execution in focus.
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: The Cooper Companies (COO - Free Report) The Cooper Companies is a global medical device company operating through two main segments: CooperVision (CVI) and CooperSurgical (CSI). CVI focuses on contact lenses, with a strong presence in daily silicone hydrogel lenses, torics, multifocals, and myopia management. Its flagship MyDay franchise, including MyDay Energys and toric/multifocal expansions, continues to capture premium share, while MiSight addresses the growing myopia epidemic. CSI provides products and services in fertility and women’s health, offering in-vitro fertilization (IVF) solutions, contraceptives such as Paragard, and office/surgical devices.
COO is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
Additionally, the company could be a top pick for growth investors. COO has a Growth Style Score of B, forecasting year-over-year earnings growth of 12.4% for the current fiscal year.
Four analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.01 to $4.63 per share. COO also boasts an average earnings surprise of +5.8%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, COO should be on investors' short list.
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +24% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: The Cooper Companies (COO - Free Report) The Cooper Companies is a global medical device company operating through two main segments: CooperVision (CVI) and CooperSurgical (CSI). CVI focuses on contact lenses, with a strong presence in daily silicone hydrogel lenses, torics, multifocals, and myopia management. Its flagship MyDay franchise, including MyDay Energys and toric/multifocal expansions, continues to capture premium share, while MiSight addresses the growing myopia epidemic. CSI provides products and services in fertility and women’s health, offering in-vitro fertilization (IVF) solutions, contraceptives such as Paragard, and office/surgical devices.
COO is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
Momentum investors should take note of this Medical stock. COO has a Momentum Style Score of A, and shares are up 4.6% over the past four weeks.
For fiscal 2026, three analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.01 to $4.63 per share. COO boasts an average earnings surprise of +5.8%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, COO should be on investors' short list.
A handful of OpenAI executives are transitioning into new roles, according to a report from Bloomberg. An OpenAI spokesperson confirmed the personnel changes to TechCrunch.
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
#1 (Strong Buy) stocks have produced an unmatched +23.93% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: The Cooper Companies (COO - Free Report) The Cooper Companies is a global medical device company operating through two main segments: CooperVision (CVI) and CooperSurgical (CSI). CVI focuses on contact lenses, with a strong presence in daily silicone hydrogel lenses, torics, multifocals, and myopia management. Its flagship MyDay franchise, including MyDay Energys and toric/multifocal expansions, continues to capture premium share, while MiSight addresses the growing myopia epidemic. CSI provides products and services in fertility and women’s health, offering in-vitro fertilization (IVF) solutions, contraceptives such as Paragard, and office/surgical devices.
COO is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.
Additionally, the company could be a top pick for growth investors. COO has a Growth Style Score of B, forecasting year-over-year earnings growth of 12.1% for the current fiscal year.
For fiscal 2026, six analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.12 to $4.62 per share. COO boasts an average earnings surprise of +4.1%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, COO should be on investors' short list.
New sustainability platform reflects company's commitment to responsible sourcing, more
efficient manufacturing, and offsetting a portion of plastic footprint*†1
, /PRNewswire/ -- CooperVision announced today the launch of its MADE BETTER™ Promise—a new global sustainability platform focused on smarter, more sustainable choices.*†1 Built on years of CooperVision innovation in sustainability, MADE BETTER™ Promise is woven throughout the life of participating products, beginning with the MyDay® daily disposable family of contact lenses.*†1
As part of the MADE BETTER™ Promise, CooperVision's MADE BETTER™ Innovation with MyDay® is introducing mindful packaging material choices and manufacturing improvements that lowers the carbon impact.*†1 The company also continues to offset a portion of MyDay® plastic footprint through its plastic neutrality program.†‡2
Key elements of CooperVision's MADE BETTER™ Innovation include:
Use of ISCC PLUS-certified materials in the packaging of participating products, making CooperVision the first and only contact lens manufacturer to do so.*†§♦1,3 The plastic within MyDay® blisters is 100% ISCC PLUS-certified bio-attributed material sourced and allocated via the ISCC mass balance approach.¶3,4 Manufacturing processes intentionally designed to reduce carbon footprint through next-generation technologies and improved resource efficiency. *†**††‡‡1,5 Use of lower-carbon energy where possible across production operations.§§6 Manufacturing sites that recycle more than 90% of waste, helping conserve natural resources.♦♦7 MADE BETTER™ Innovation also encompasses CooperVision's plastic neutrality program with Plastic Bank, which supports the removal of plastic waste from coastal communities while creating positive socioeconomic impact.†‡2 To date, the program has enabled the collection and recycling of more than 659 million plastic bottles from coastal areas where plastic pollution is prevalent.¶¶8
"CooperVision's sustainability progress begins with innovation—in materials, manufacturing, and the way we think about the full life cycle of our products.*†1 MADE BETTER™ Promise reflects how we are turning those innovations into real–world impact through thoughtful choices that benefit both People + Planet,*♦♦♦1,9 said Aldo Zucaro, Senior Director of Corporate Responsibility, CooperCompanies. "We're off to a strong start, delivering practitioners and their patients the same MyDay®—just made with less carbon." ****††††6
CooperVision's MADE BETTER™ Promise is an ongoing global commitment, with continued advancements in materials, technologies, and processes intended to further reduce environmental impact over time.*1
*CooperVision's MADE BETTER Innovation program has introduced lower-carbon inputs with traceable sourcing - including ISCC PLUS-certified, lower-carbon plastic and lower-carbon aluminum - into the primary packaging of the MyDay® range of products. It also refers to process improvements that have reduced waste, improved energy efficiency, and lowered greenhouse gas emissions during production of the MyDay® range of products. Methods and verification information are available at [coopervision.com/sustainability/methods].
†Through its partnership with Plastic Bank, CooperVision offsets a portion of its plastic footprint by funding the collection and recycling of plastic waste, equivalent in weight to the plastic used in participating soft contact lens products sold in participating countries, gathered within 30 miles of oceans or waterways in countries where Plastic Bank operates. Plastic weight is based on the total weight of plastic in the lens, blister, and secondary packaging, including laminates, adhesives, and auxiliary inputs (e.g. ink). This does not include plastic used during the manufacturing process.
‡Plastic used in participating CooperVision soft contact lens products is determined by the weight of plastic in the blister, the lens, and the secondary package, including laminates, adhesives, and auxiliary inputs (e.g. ink). The determination does not include plastic used during the manufacturing process for both these products and their packaging.
§'Packaging' refers to the blister pack that directly encloses each contact lens - the plastic tray sealed with an aluminum foil lid.
♦Determination is based on a review of the ISCC PLUS-certified public license database and publicly available information. ISCC PLUS-certified licenses are issued at supplier/site level and may not identify downstream brands. As of November 6, 2025, no other contact lens manufacturers were identified as using ISCC PLUS-certified plastic. ISCC License number ISCC-L-228, valid beginning April 6, 2026, along with CooperVision's internal documentation shows that 100% of the polypropylene used within the MyDay® blisters is ISCC PLUS-certified bio-attributed material sourced and allocated via the mass balance approach; certification does not imply physical segregation.
¶Foil lidding atop of the MyDay® blisters and the contact lenses themselves are not ISCC PLUS-certified.
**Refers to continuous manufacturing improvement processes undertaken by CooperVision to increase efficiency
††Carbon footprint is limited to Scope 1 and 2 emissions, defined as: Scope 1 emissions are direct emissions from owned or controlled sources. Scope 2 emissions are indirect emissions from the generation of purchased energy.
‡‡CooperVision's 2021 and 2022 Environmental, Social, and Governance Reports.
§§The MyDay® range of products are manufactured at two facilities that use lower-carbon energy sources. At CooperVision's Juana Díaz, Puerto Rico site, combined heat and power (CHP) technology generates electricity and thermal energy more efficiently than conventional grid-supplied electricity and separate heating systems. Based on CooperVision's scope 1 and scope 2 emissions data, total greenhouse gas emissions per manufactured lens at this facility in 2024 were approximately 30% lower than in 2021, prior to CHP startup. At its manufacturing facilities in the UK, CooperVision purchases 100% renewable energy.
♦♦SCS Global Services Certificate No. SCS-ZW-0018 verifies a recycling rate of 94.7% for the Juana Díaz, PR facility. SCS Global Services is an international leader in third-party certification, validation, and verification for environmental sustainability. CooperVision's internal records demonstrate an average recycling rate of over 90% for its MyDay® manufacturing facilities in the UK.
¶¶CooperVision, through its collaboration with Plastic Bank, has collected and recycled approximately 12.4M kg of plastic waste gathered within 30 miles of oceans or waterways in countries where Plastic Bank operates as of February 2026. Using Plastic Bank's metric of 1kg of plastic equaling 50 standard 202mm bottles, that will be the equivalent of approximately 659M plastic bottles.
♦♦♦As of October 3, 2025, more than 7,000 Plastic Bank collection members across 500+ communities in Indonesia, Egypt, and the Philippines have exchanged collected plastic waste for income and life-improving benefits (such as insurance, digital connectivity, grocery vouchers, and school supplies) through CooperVision's plastic neutrality program with Plastic Bank, cumulative since January 2021.
****Results compare 2024 with a 2021 baseline. Full life cycle assessment has been conducted in accordance with ISO 14067 and verified through independent critical review from a cradle-to-grave basis, which covers all product stages from raw material extraction to end-of-life. Details on methodology and verification are available at [coopervision.com/sustainability/methods].
††††Carbon reduction' and/or 'lower carbon' refer to a reduction in total greenhouse gas emissions, expressed as carbon dioxide equivalent (CO2e). No carbon offsets are used.
References:
CVI data on file, 2023-2025 CVI data on file, 2024. CVI data on file, 2025. International Sustainability & Carbon Certification, 2025, https://iscc-system.org/about/who-we-are.] CVI data on file, 2023. CVI data on file, 2021-2025. CVI data on file, 2024-2025. CVI data on file as of 03/2026. Plastic Bank, CVI data on file, 2025 SA17810/APP163993
About CooperVision
CooperVision, a division of CooperCompanies (Nasdaq:COO), is one of the world's leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric, and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women's healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com.
Media Contact
Heather Kowalczyk, APR
McDougall Communications for CooperVision
[email protected] or +1.585.434.2148
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
#1 (Strong Buy) stocks have produced an unmatched +23.93% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: The Cooper Companies (COO - Free Report) The Cooper Companies is a global medical device company operating through two main segments: CooperVision (CVI) and CooperSurgical (CSI). CVI focuses on contact lenses, with a strong presence in daily silicone hydrogel lenses, torics, multifocals, and myopia management. Its flagship MyDay franchise, including MyDay Energys and toric/multifocal expansions, continues to capture premium share, while MiSight addresses the growing myopia epidemic. CSI provides products and services in fertility and women’s health, offering in-vitro fertilization (IVF) solutions, contraceptives such as Paragard, and office/surgical devices.
COO is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 15.22; value investors should take notice.
Six analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.12 to $4.62 per share. COO also boasts an average earnings surprise of +4.1%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, COO should be on investors' short list.
Investors interested in Medical - Dental Supplies stocks are likely familiar with The Cooper Companies (COO) and Straumann Holding AG (SAUHY). But which of these two stocks presents investors with the better value opportunity right now?
The Zacks Medical - Dental Supplies industry in the Medical sector is likely to continue its upward momentum in 2026, backed by persistent innovation, an aging population with increasing healthcare needs and normalized orders following significant destocking since COVID-19.
In 2026, healthcare is transitioning toward AI-integrated, digital-first operating models, with clinical-grade AI embedded in workflows to automate documentation, enhance decision-making and personalize patient engagement. These tools improve efficiency and reduce administrative burden while supporting predictive, proactive care delivery.
Automation is also expanding into operational domains, including logistics and robotics, improving precision and throughput, though efficiency gains vary by deployment. Stricter regulatory frameworks in the United States and Europe are reinforcing compliance requirements for AI-enabled, high-value medical technologies.
Strategically, companies are prioritizing high-growth specialties and precision medicine, leveraging genomics and AI-driven diagnostics to enable earlier, individualized interventions. Biosimilars remain a structural growth driver as biologics lose exclusivity, while care delivery continues to decentralize toward ambulatory, virtual, and home-based models aligned with cost efficiency and patient preference.
Per a Markets and Markets report, the global medical supplies industry is expected to reach $163.5 billion by 2027, at a CAGR of 3.4% in the 2022-2027 period. Industry participants, such as Cardinal Health (CAH - Free Report) , Becton, Dickinson and Company (BDX - Free Report) and The Cooper Companies (COO - Free Report) , are likely to ride on the favorable macro trends amid lingering tariff risks.
Industry Description The global dental industry consists of companies that design, develop, make and market dental products, such as consumables, laboratory products and specialty items. Some of these companies also offer software and systems for practice management, patient education and office administration. Dental stocks have been drawing attention amid a recovery in sales following the weakness caused by pandemic-induced disruptions. The market has been recovering and maintaining its position.
Dental care is provided based on the advice and recommendations of the American Dental Association and the Centers for Disease Control and Prevention. Thanks to the rebound seen among companies in this space, patient volumes have been increasing steadily following the removal of COVID-19 restrictions.
Major Trends Shaping the Future of the Medical Dental Supplies Industry Increasing Burden of Oral Diseases and an Aging Population: The U.S. dental equipment market is structurally supported by demographic aging and rising disease prevalence. Older cohorts account for a disproportionate share of restorative and surgical procedures, reflecting a higher incidence of caries, periodontal disease, and tooth loss. With the 65+ population expanding, demand visibility remains strong, reinforcing procedure volumes and equipment utilization across practices.
Technological Innovations: Technology remains a primary growth catalyst, with CAD/CAM, 3D imaging, AI-driven diagnostics, and digital workflows improving clinical precision and chairside efficiency. These innovations expand procedural capabilities, reduce turnaround times, and support higher throughput, thereby driving adoption of advanced equipment and consumables.
Growing Awareness and Emphasis on Preventive Care: Rising awareness of oral hygiene and preventive care is shifting demand toward early-stage interventions. Increased utilization of fluoride treatments, sealants, and prophylaxis products reflects a broader transition toward prevention-focused dentistry, supporting recurring revenue streams within consumables.
Minimally Invasive and Cosmetic Dentistry Trends: Patient preference is increasingly skewed toward minimally invasive and aesthetic procedures, including whitening and veneers. This trend is expanding demand for specialized materials and precision equipment, while also increasing procedure frequency and average spend per patient.
Expansion of Dental Clinics and Group Practices: The ongoing expansion of dental clinics, DSOs, and hospital-based practices is structurally increasing equipment demand. Higher patient throughput, standardized treatment protocols, and procurement efficiencies are driving consistent product utilization across growing care networks.
Regional Market Growth Drivers: Emerging markets, particularly in Asia-Pacific, are exhibiting above-average growth due to rising healthcare expenditure, improving access, and supportive policy frameworks. Dental tourism and expanding middle-class demand are further accelerating equipment adoption in these regions.
Government Initiatives and Insurance Coverage: Supportive public health policies and expanding insurance coverage are improving affordability and access to dental care. This is driving higher treatment volumes and increasing consumption of both preventive and therapeutic dental products globally.
Economic Factors and Healthcare Infrastructure: Developed markets benefit from strong healthcare infrastructure and higher disposable income, enabling faster adoption of premium dental technologies. Established reimbursement systems and patient awareness further support sustained demand for advanced procedures and equipment.
Tariff War Raises Uncertainty: Recent U.S. tariff measures have fueled inflation across imported dental inputs, disrupting supply chains and compressing margins for manufacturers and distributors. Pricing pass-through is elevating treatment costs, potentially moderating demand and inventory cycles in the near term.
To mitigate tariff exposure, industry participants are gradually diversifying sourcing toward domestic and regional manufacturing. However, supply-chain realignment remains incremental, and trade-related volatility continues to pose execution risks for procurement and pricing strategies.
Zacks Industry Rank The Zacks Medical Dental Supplies industry falls within the broader Zacks Medical sector.
It carries a Zacks Industry Rank #85, which places it in the top 35% of 243 Zacks industries.
The group’s Zacks Industry Rank, which is basically the average of the Zacks Rank of all member stocks, indicates dull near-term prospects. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Before we present a few dental supply stocks that you may want to consider for your portfolio, let’s take a look at the industry’s recent stock-market performance and valuation picture.
Industry Performance The industry has outperformed its sector but underperformed the S&P 500 composite in the past year.
Stocks in this industry collectively gained 15.4% compared with the Zacks Medical sector’s rise of 8.3%. The S&P 500 has surged 42.8% in the same time frame.
One-Year Price Performance
Industry's Current Valuation On the basis of the forward 12-month price-to-earnings (P/E), which is commonly used for valuing medical stocks, the industry is currently trading at 17.35X compared with the S&P 500’s 22.18X and the sector’s 20.27X.
Over the past five years, the industry has traded as high as 21.75X and as low as 15.94X, with the median being 18.57X, as the charts show.
Price-to-Earnings Forward Twelve Months (F12M)
Price-to-Earnings Forward Twelve Months (F12M)
3 Promising Dental Supply Stocks Cardinal Health is expected to maintain its operational momentum in 2026, driven by steady performance across both its Pharmaceutical and Medical segments. In Pharmaceutical, growth will likely come from continued volume gains with large retail chains, strong specialty distribution and expanding partnerships with health systems.
Specialty therapeutics, particularly in oncology and chronic care, remain key revenue drivers, supported by Cardinal Health’s extensive distribution network and manufacturer service offerings. Rising biosimilar adoption and growing demand for patient support programs further strengthen the segment’s outlook.
The Medical segment continues to benefit from recovering procedural volumes, solid demand for Cardinal Health’s at-Home Solutions and greater supply-chain stability. Efforts to simplify the product portfolio, modernize manufacturing, and expand automation are boosting efficiency and margins. New product launches in single-use surgical devices and lab testing consumables are also reinforcing its competitive position.
Cardinal Health faces several challenges. Competitive pricing pressures, generic deflation, and inflation-related costs for freight and labor could affect margins. Regulatory uncertainty around drug pricing and biosimilar reimbursement, along with consolidation among retail pharmacy customers, may add headwinds. Execution on portfolio and cost transformation initiatives remains an area to watch in the coming quarters.
CAH expects adjusted EPS to be in the range of $10.15-$10.35 for fiscal 2026. The company expects revenues from its Pharmaceutical segment to grow 15-17% year over year. Revenues from the Medical segment are estimated to grow 1-3% and those from the Other segment are likely to increase 26-28%.
The Zacks Consensus Estimate for fiscal 2026 revenues indicates an improvement of 16.5% from the year-ago reported figure, while the same for earnings implies a rise of 25.2%. CAH carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Price and Consensus: CAH
Cooper Companies entered 2026 with improving operating momentum, underpinned by product innovation, market share gains and operational efficiency. The core CooperVision segment remains the primary growth engine, supported by continued expansion of its premium daily silicone hydrogel portfolio, particularly MyDay and specialty lenses such as torics and multifocals.
New product rollouts and contract wins, alongside rising adoption of myopia control solutions like MiSight, are expected to sustain above-market growth, with management highlighting strong clinician uptake and long-term demand visibility.
Geographically, the Americas and EMEA are demonstrating solid commercial traction, while Asia-Pacific remains a near-term drag due to weakness in legacy hydrogel products, particularly in Japan. However, ongoing product launches, leadership changes and distribution investments are expected to restore regional growth by the second half of the year.
CooperSurgical adds a secondary growth lever, with fertility markets showing early signs of recovery driven by improving IVF cycles and renewed clinic investments in advanced technologies. Growth in genomics and consumables further supports this trajectory.
Operationally, margin expansion is being driven by restructuring-led cost synergies, disciplined expense management and increasing use of AI-enabled tools. Strong free cash flow supports reinvestment in growth initiatives, share buybacks and debt reduction.
Key risks include continued softness in Asia-Pacific, geopolitical uncertainty affecting fertility markets, pricing pressures in select regions and tariff-related cost headwinds. Execution on product launches and sustained recovery in underperforming markets remain critical to achieving full-year targets.
Cooper Companies expects its fiscal 2026 EPS to be in the range of $4.58-$4.66. The company expects total revenues to grow 4.5-5.5% organically.
The Zacks Consensus Estimate for fiscal 2026 revenues indicates a gain of 5.6% from the year-ago reported figure, while the same for earnings implies an improvement of 12.1%. It carries a Zacks Rank of 2 at present.
Price and Consensus: COO
Becton, Dickinson and Company, popularly known as BD, entered 2026 in a transitional yet strategically focused position after separating its Life Sciences business and evolving into a more streamlined pure-play medtech company. Management’s growth strategy is centered on scaling high-margin, high-growth platforms aligned with structural healthcare trends, including connected care, biologic drug delivery and advanced interventional solutions.
These segments are already demonstrating strong traction, with double-digit growth in biologics, pharmacy automation, and tissue regeneration, alongside high single-digit expansion in advanced patient monitoring.
Commercial execution and innovation are key growth levers. Expanded sales force investments, new product launches such as Pyxis Pro and HemoSphere Stream, and accelerated R&D timelines are expected to enhance market share gains and broaden addressable markets.
The company’s large installed base and consumables-driven model, accounting for over 90% of revenue, provide recurring revenue visibility and resilience. Operational initiatives, including manufacturing network simplification and productivity improvements, further support margin expansion and cash flow generation.
Growth in 2026 remains tempered by several headwinds. Approximately 10% of the portfolio faces pressure from China volume-based procurement, vaccine demand softness, and ongoing Alaris-related dynamics. Tariffs are also weighing on margins, contributing to earnings pressure despite operational efficiencies. While management expects these factors to normalize over time, they are likely to constrain near-term performance.
BD expects its fiscal 2026 earnings per share (EPS) to be in the range of $12.35-$12.65. The company expects total revenues to grow low single-digit percentage points.
For this Franklin Lakes, NJ-based company, the Zacks Consensus Estimate for fiscal 2026 revenues indicates a 12.3% decline from the prior-year reported figure, while the same for earnings implies a decrease of 12.9%. Presently, the company carries a Zacks Rank #3 (Hold).
Shahar Tamari, Chief Operating Officer (COO) of Global-E Online (GLBE 0.81%), reported the sale of 25,949 shares of Common Stock for approximately $903,000, according to an SEC Form 4 filing.
Transaction summaryMetricValueShares sold (direct)25,949Transaction value$902,766Post-transaction shares (direct)3,790,225Post-transaction value (direct ownership)$128.53 millionTransaction value based on SEC Form 4 reported price ($34.79); post-transaction value based on April 17, 2026, market close ($33.91).
Key questionsHow does this sale compare to Shahar's historical trading activity?
This was the largest single-day sale by Shahar in the past five transactions, with the previous maximum at 16,666 shares, indicating a step-up in dollar volume but still representing less than 1% of direct holdings.What is the current scale of Shahar's ownership relative to the company's equity?
After the transaction, Tamari directly holds 3,790,225 shares, equating to approximately 2.24% of the company's outstanding shares as of the latest available data.Were any derivative securities or indirect holdings involved in this transaction?
The transaction involved only directly held Common Stock, with no sales from indirect accounts or derivative exercises.Does the sale reflect a change in trading cadence or capacity?
The transaction size increased versus prior sales, but this is explained by capacity: Tamari's aggregate holdings remain largely intact, and the percentage sold is consistent with recent activity, suggesting routine portfolio management rather than a strategic shift.Company overviewMetricValueRevenue (TTM)$962.20 millionNet income (TTM)$68.27 millionEmployees1,2191-year price change5.51*1-year price change calculated as of April 20, 2026.
Company snapshotProvides a technology platform enabling direct-to-consumer cross-border e-commerce, facilitating online transactions for international shoppers and merchants.Targets online retailers and brands seeking to expand internationally, with a focus on merchants in Israel, the United Kingdom, the United States, and other global markets.Global-E Online Ltd. operates at scale as a cross-border e-commerce enabler, supporting over 1,000 employees and driving nearly $1 billion in annual revenue. The company’s strategy centers on providing seamless international shopping experiences for both merchants and consumers, leveraging proprietary technology and a global network.
What this transaction means for investorsGlobal E-Online has performed well, rising 5.51% over the past year (as of April 20). So why did its COO, Shahar Tamari, sell part of his stock holdings? In this case, it appears to be a minor transaction unrelated to stock performance or future outlook, as it represented approximately 1% of his total holdings.
Based in Israel, the company has been making steady progress as a leading cross-border e-commerce platform. This is an industry that has seen recent volatility due to geopolitical issues such as tariffs.
Its main attraction is its software program aimed at simplifying international commerce between merchants and consumers, and it has recently partnered with major consumer and luxury brands such as Victoria’s Secret (VSCO +6.12%) and Harrods. In general, growth appears strong as more consumers embrace global trade, and analysts expect earnings to trend upward.
Pamela Kock has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Global-E Online and Victoria's Secret & Co. The Motley Fool has a disclosure policy.
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
#1 (Strong Buy) stocks have produced an unmatched +23.93% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: The Cooper Companies (COO - Free Report) The Cooper Companies is a global medical device company operating through two main segments: CooperVision (CVI) and CooperSurgical (CSI). CVI focuses on contact lenses, with a strong presence in daily silicone hydrogel lenses, torics, multifocals, and myopia management. Its flagship MyDay franchise, including MyDay Energys and toric/multifocal expansions, continues to capture premium share, while MiSight addresses the growing myopia epidemic. CSI provides products and services in fertility and women’s health, offering in-vitro fertilization (IVF) solutions, contraceptives such as Paragard, and office/surgical devices.
COO is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.
Additionally, the company could be a top pick for growth investors. COO has a Growth Style Score of B, forecasting year-over-year earnings growth of 12.1% for the current fiscal year.
Seven analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.11 to $4.62 per share. COO also boasts an average earnings surprise of +4.1%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, COO should be on investors' short list.
SAN RAMON, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today that its Board of Directors has appointed Paul Keel as an independent director, effective July 1, 2026. Mr. Keel has also been appointed to serve on the Audit Committee when he joins the Board.
“We are delighted to welcome Paul to our Board as a new Director,” said Colleen Jay, Chair of the Board of CooperCompanies. “His experience as a CEO in the medical device sector, along with a successful track record of leading complex global operations, will be a significant asset as Cooper continues to execute its strategy and create long-term value for patients, customers, and shareholders.”
Mr. Keel has served as President and Chief Executive Officer of Envista Holdings Corporation (NYSE: NVST), a global specialty medical technology company, since 2024. Prior to joining Envista, Mr. Keel served as CEO of Smiths Group plc (LON: SMIN), a diversified global industrial technology company and FTSE constituent, from 2021 to 2024. Earlier, he spent 16 years at 3M, serving in various leadership roles, including Group President of 3M Consumer Business, President of 3M Medical, President of 3M Unitek, SVP of Manufacturing & Supply Chain, and SVP of Marketing, Sales & Business Development. Mr. Keel’s career also includes roles at General Mills, General Electric, Norwest Equity Partners, and McKinsey & Company. He holds an MBA from Harvard Business School and a BA in Economics from Carleton College.
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life’s beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women’s healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com.
Forward-Looking Statements
This press release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to the Company’s efforts to enhance long-term shareholder value, plans, strategies, future actions, and other statements of which are other than statements of historical fact, are forward-looking. Forward-looking statements necessarily depend on assumptions, data, or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Statements regarding future events and performance and contain words such as “expects” and similar words or phrases. A wide range of factors could materially affect future developments, including, but not limited to, uncertainties related to market conditions and other factors set forth in our other filings with the United States Securities and Exchange Commission, including our most recent Annual Report on Form 10-K. These risks and uncertainties may cause actual future results or actions to be materially different than those expressed in such forward-looking statements. We do not intend, or undertake any duty, to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contact:
Kim Duncan
Vice President, Investor Relations and Risk Management
Investors interested in Medical - Dental Supplies stocks are likely familiar with The Cooper Companies (COO - Free Report) and Straumann Holding AG (SAUHY - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits.
Right now, The Cooper Companies is sporting a Zacks Rank of #2 (Buy), while Straumann Holding AG has a Zacks Rank of #4 (Sell). This system places an emphasis on companies that have seen positive earnings estimate revisions, so investors should feel comfortable knowing that COO is likely seeing its earnings outlook improve to a greater extent. But this is only part of the picture for value investors.
Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels.
Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use.
COO currently has a forward P/E ratio of 13.27, while SAUHY has a forward P/E of 27.23. We also note that COO has a PEG ratio of 1.58. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. SAUHY currently has a PEG ratio of 2.27.
Another notable valuation metric for COO is its P/B ratio of 1.43. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. For comparison, SAUHY has a P/B of 6.65.
These are just a few of the metrics contributing to COO's Value grade of B and SAUHY's Value grade of D.
COO sticks out from SAUHY in both our Zacks Rank and Style Scores models, so value investors will likely feel that COO is the better option right now.
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: The Cooper Companies (COO - Free Report) The Cooper Companies is a global medical device company operating through two main segments: CooperVision (CVI) and CooperSurgical (CSI). CVI focuses on contact lenses, with a strong presence in daily silicone hydrogel lenses, torics, multifocals, and myopia management. Its flagship MyDay franchise, including MyDay Energys and toric/multifocal expansions, continues to capture premium share, while MiSight addresses the growing myopia epidemic. CSI provides products and services in fertility and women’s health, offering in-vitro fertilization (IVF) solutions, contraceptives such as Paragard, and office/surgical devices.
COO is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 13.2; value investors should take notice.
One analyst revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.02 to $4.62 per share. COO boasts an average earnings surprise of +4.1%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, COO should be on investors' short list.
Investors with an interest in Medical - Dental Supplies stocks have likely encountered both The Cooper Companies (COO) and Straumann Holding AG (SAUHY). But which of these two stocks is more attractive to value investors?
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (MonjuviÂ/Min
Key Takeaways COO is set to report Q2 FY26 on June 4; sales are seen at $1.05B ( 5.2%) and EPS at $1.10 ( 14.6%).CooperVision likely led growth via MyDay daily silicone hydrogel gains, plus contract wins and launches.CooperSurgical trends improved as IVF stabilized; restructuring and AI automation likely supported margin. The Cooper Companies (COO - Free Report) is scheduled to report second-quarter fiscal 2026 results on June 4, after market close.
The Zacks Consensus Estimate for sales is pegged at $1.05 billion, implying 5.2% year-over-year growth. The bottom-line estimate is pinned at $1.10 per share, suggesting growth of 14.6%.
The EPS estimates have remained stable over the past seven days.
Image Source: Zacks Investment Research
Earnings Surprise HistoryThe company delivered an earnings surprise of 6.8% in the last reported quarter. Its earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 4.11%.
What the Zacks Model Unveils for COOOur proven model does not conclusively predict an earnings beat for The Cooper Companies this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.
COO’s Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, for this company is 0.00%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank of COO: The company carries a Zacks Rank #2 at present.
Factors Likely to Drive COO’s Q2 PerformanceThe Cooper Companies is expected to have delivered a solid fiscal second-quarter performance, supported by continued strength in its CooperVision business, ongoing momentum from new product launches and benefits from operational efficiency initiatives. Following a strong first quarter, management raised its full-year adjusted EPS guidance to $4.58-$4.66, reflecting confidence in underlying demand trends and execution across both business segments.
The CooperVision (CVI) segment likely remained the primary growth driver during the quarter. The company is likely to have entered second-quarter fiscal 2026 with strong momentum in the Americas and EMEA, supported by expanding customer partnerships, branded contract wins and private-label launches. Continued adoption of premium daily silicone hydrogel lenses, particularly the MyDay portfolio, likely contributed to revenue growth. Management previously highlighted strong performance from MyDay multifocal, Energys and toric lenses, each benefiting from a favorable product mix and increasing market penetration.
Myopia control products are expected to have remained a meaningful growth contributor. MiSight revenues grew 23% in first-quarter fiscal 2026, supported by recent launches in Japan and the rollout of MyDay MiSight across EMEA. Early clinician adoption and strong professional engagement programs suggest demand trends likely remained favorable throughout the quarter, reinforcing CooperVision’s long-term growth outlook in the category.
Within the CooperSurgical (CSI) segment, fertility trends are expected to have improved sequentially as underlying IVF market conditions stabilized. Management previously noted improving IVF cycles in the United States and parts of Europe, alongside stronger demand for genomics, media, ZyMot and Witness products. While uncertainty surrounding the Middle East fertility market may have persisted, overall business trends appeared to be moving in a favorable direction.
Regionally, the Americas and EMEA were expected to maintain healthy growth trajectories. However, Asia Pacific likely remained a near-term headwind due to continued softness in legacy hydrogel products in Japan. Geopolitical uncertainties affecting fertility markets in the Middle East and competitive pricing pressures in parts of Asia may have tempered growth. Management expects to improve momentum in the second half of fiscal 2026 as product launches, contract wins and fertility market recovery begin to translate into stronger revenue growth.
On the profitability front, restructuring benefits, AI-enabled workflow automation and disciplined cost management are expected to have supported margin expansion. The company’s organizational changes and technology investments generated operating leverage in first-quarter fiscal 2026 and are expected to have remained an important contributor to the fiscal second-quarter earnings performance.
COO’s Share Price PerformanceShares of COO have lost 27.4% in the year-to-date period compared with the industry’s 10.3% decline. However, the S&P 500 Index has increased 11.3% in the same time frame.
Image Source: Zacks Investment Research
Stocks Worth a LookHere are some medical product stocks worth considering as these have the right combination of elements to post an earnings beat next reporting cycle.
Stryker (SYK - Free Report) has an Earnings ESP of +2.74% and a Zacks Rank #3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
SYK’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being -1.82%. According to the Zacks Consensus Estimate, SYK’s second-quarter EPS is expected to improve 11.5% from the year-ago reported figure.
Merit Medical Systems (MMSI - Free Report) has an Earnings ESP of +1.04% and a Zacks Rank of 3 at present.
MMSI’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 12.47%. The Zacks Consensus Estimate for MMSI’s second-quarter EPS implies a decline of 4.9% from the year-ago reported figure.
DexCom (DXCM - Free Report) has an Earnings ESP of +1.33% and a Zacks Rank of 3 at present.
DXCM’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 9.37%. The Zacks Consensus Estimate for DXCM’s second-quarter EPS implies a gain of 25% from the year-ago reported figure.
SAN RAMON, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal second quarter ended April 30, 2026.
Second quarter 2026 revenue of $1.082 billion, up 8%, or up 5% organically, from last year's second quarter.Second quarter 2026 GAAP diluted earnings per share (EPS) of $(0.40), down $0.84 from last year's second quarter driven by a litigation-related charge to resolve outstanding claims associated with a December 2023 voluntary product recall at CooperSurgical.Second quarter 2026 Non-GAAP diluted EPS of $1.21, up $0.25 or 26% from last year's second quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below.
"We delivered a strong second quarter, achieving record revenue and non-GAAP earnings per share while marking our tenth consecutive quarter of exceeding consensus earnings expectations," said Al White, CooperCompanies' President and CEO. "Our performance reflects solid execution across our businesses, supported by new product launches, favorable demand drivers, and ongoing focus on operational discipline. In addition, we have reached agreements to resolve substantially all of the claims related to CooperSurgical's fertility media recall, representing an important step in addressing this issue and allowing us to move forward with our strategic review. Moving forward, we are focused on driving sustainable, profitable growth and strong cash flow, while maintaining discipline in a dynamic operating environment."
Second Quarter Operating Results
Revenue of $1.082 billion, up 8% from last year’s second quarter, up 5% in constant currency, up 5% organically.Gross margin of 68% similar to last year's second quarter. On a non-GAAP basis, gross margin was also similar to last year at 68%, with positive FX offsetting higher costs including tariffs.Operating margin of negative 3% compared with 18% in last year’s second quarter, primarily reflecting higher SG&A expenses, due to a $271.6 million litigation-related charge. On a non-GAAP basis, operating margin was up 260 basis points from last year to 27%, reflecting disciplined execution and meaningful synergies from last year's reorganization.Interest expense of $20.9 million compared with $24.2 million in last year's second quarter driven by lower interest rates and lower average debt. On a non-GAAP basis, interest expense was $20.9 million, down from $23.5 million.Cash provided by operations of $182.8 million, offset by capital expenditures of $86.4 million resulted in free cash flow of $96.4 million.
Second Quarter CooperVision (CVI) Revenue
Revenue of $723.5 million, up 8% from last year’s second quarter, up 4% in constant currency, up 4% organically.Revenue by category: % change y/y (In millions) Reported
Currency Impact
Constant Currency
Acquisitions and Divestitures
Organic
2Q26 Toric and multifocal$364.9 11% (4)% 7% —% 7% Sphere, other 358.6 5% (4)% 1% —% 1% Total$723.5 8% (4)% 4% —% 4% Revenue by geography:
% change y/y (In millions) Reported
Currency Impact
Constant Currency
Acquisitions and Divestitures
Organic
2Q26 Americas$303.2 7% —% 7% —% 7% EMEA 289.7 17% (11)% 6% —% 6% Asia Pacific 130.6 (6)% —% (6)% —% (6)% Total$723.5 8% (4)% 4% —% 4% Second Quarter CooperSurgical (CSI) Revenue
Revenue of $358.0 million, up 8% from last year's second quarter, up 6% in constant currency, up 6% organically.
Revenue by category:
% change y/y (In millions) Reported
Currency Impact
Constant Currency
Acquisitions and Divestitures
Organic
2Q26 Office and surgical$214.2 4% —% 4% —% 4% Fertility 143.8 13% (3)% 10% —% 10% Total$358.0 8% (2)% 6% —% 6% Other
During the second quarter, the Company repurchased $13.1 million of common stock, approximately 174 thousand shares, at an average share price of $75.84. The program has $860.8 million of remaining availability.Recorded a $271.6 million net pre-tax charge within SG&A related to certain product-related litigation matters associated with a December 2023 voluntary recall of embryo culture media at CooperSurgical, consisting of $324.1 million of accrued litigation liabilities, partially offset by $52.5 million of expected insurance recoveries. Fiscal Year 2026 Financial Guidance
The Company updated its fiscal year 2026 financial guidance. Details are summarized as follows:
Fiscal 2026 total revenue of $4.285 - $4.321 billion (organic growth of 3.5% to 4.5%) CVI revenue of $2.883 - $2.908 billion (organic growth of 3.5% to 4.5%)CSI revenue of $1.402 - $1.414 billion (organic growth of 4% to 5%) Fiscal 2026 non-GAAP diluted EPS of $4.58 - $4.66Reaffirm previously communicated long-term free cash flow objective exceeding $2.2 billion for fiscal years 2026 through 2028
Non-GAAP diluted earnings per share guidance excludes amortization and impairment of intangible assets, and certain income or gains and charges or expenses including acquisition and integration costs which we may incur as part of our continuing operations.
With respect to the Company’s guidance expectations, the Company has not reconciled non-GAAP diluted earnings per share guidance to GAAP diluted earnings per share due to the inherent difficulty in forecasting acquisition-related, integration and restructuring charges and expenses, which are reconciling items between the non-GAAP and GAAP measures. Due to the unknown effect, timing and potential significance of such charges and expenses that impact GAAP diluted earnings per share, the Company is not able to provide such guidance.
Reconciliation of Selected GAAP Results to Non-GAAP Results
To supplement our financial results and guidance presented on a GAAP basis, we provide non-GAAP measures such as non-GAAP gross margin, non-GAAP operating margin, non-GAAP diluted earnings per share, as well as constant currency and organic revenue growth because we believe they are helpful for the investors to understand our consolidated operating results. Management uses supplemental non-GAAP financial measures internally to understand, manage and evaluate our business, to make operating decisions, and to plan and forecast for future periods. The non-GAAP measures exclude costs which we generally would not have otherwise incurred in the periods presented as a part of our continuing operations. We provide further details of the non-GAAP adjustments made to arrive at our non-GAAP measures in the GAAP to non-GAAP reconciliations below. Our non-GAAP financial results and guidance are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read only in conjunction with our consolidated financial statements prepared in accordance with GAAP.
To present constant currency revenue growth, current period revenue for entities reporting in currencies other than the United States dollar are converted into United States dollars at the average foreign exchange rates for the corresponding period in the prior year. To present organic revenue growth, we excluded the effect of foreign currency fluctuations and the impact of any acquisitions, divestitures and discontinuations that occurred in the comparable period.
We define the non-GAAP measure of free cash flow as cash provided by operating activities less capital expenditures. We believe free cash flow is useful for investors as an additional measure of liquidity because it represents cash that is available to grow the business, make strategic acquisitions, repay debt, or buyback common stock. Management uses free cash flow internally to understand, manage, make operating decisions and evaluate our business. In addition, we use free cash flow to help plan and forecast future periods.
Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.
THE COOPER COMPANIES, INC. AND SUBSIDIARIES GAAP to Non-GAAP Reconciliation
Gross Margin, Operating Margin, and EPS Three Months Ended April 30,Six Months Ended April 30,(In millions) 2026Margin % 2025Margin % 2026Margin % 2025Margin %GAAP Gross Profit$735.468%$679.168%$1,430.668%$1,339.368%Acquisition and integration-related charges(1) ——% 2.2—% ——% 3.8—%Exit of business(2) ——% ——% 1.8—% ——%Medical device regulations(3) 0.7—% 0.7—% 1.4—% 1.3—%Total 0.7—% 2.9—% 3.2—% 5.1—%Non-GAAP Gross Profit$736.168%$682.068%$1,433.868%$1,344.468% Three Months Ended April 30,Six Months Ended April 30,(In millions) 2026 Margin % 2025Margin % 2026Margin % 2025Margin %GAAP Operating Income (Loss)$(31.0)(3)%$184.818%$181.89%$366.819%Amortization of acquired intangibles 47.7 4% 49.85% 95.65% 99.45%Acquisition and integration-related charges(1) — —% 9.61% ——% 13.91%Exit of business(2) — —% ——% 1.8—% ——%Medical device regulations(3) 2.6 —% 5.31% 6.9—% 10.7—%Business optimization charges(4) 1.1 —% ——% 3.0—% ——%Other(5) 276.8 26% ——% 283.513% 0.6—%Total 328.2 30% 64.77% 390.818% 124.66%Non-GAAP Operating Income$297.2 27%$249.525%$572.627%$491.425% Three Months Ended April 30,Six Months Ended April 30,(In millions, except per share amounts) 2026 EPS 2025 EPS 2026 EPS 2025 EPSGAAP Net Income (Loss)$(77.9)$(0.40)$87.7 $0.44 $52.9 $0.27 $192.0 $0.96 Amortization of acquired intangibles 47.7 0.24 49.8 0.24 95.6 0.48 99.4 0.49 Acquisition and integration-related charges(1) — — 9.6 0.05 — — 13.9 0.07 Exit of business(2) — — — — 1.8 0.01 — — Medical device regulations(3) 2.6 0.01 5.3 0.02 6.9 0.03 10.7 0.05 Business optimization charges(4) 1.1 0.01 — — 3.0 0.02 — — Other(5) 277.6 1.42 17.4 0.09 285.2 1.46 19.9 0.10 Tax effects related to the above items (55.4) (0.28) (11.1) (0.06) (70.6) (0.36) (25.8) (0.13)Intra-entity asset transfers(6) 41.7 0.21 34.8 0.18 79.6 0.40 67.8 0.34 Total 315.3 1.61 105.8 0.52 401.5 2.04 185.9 0.92 Non-GAAP Net Income$237.4 $1.21 $193.5 $0.96 $454.4 $2.31 $377.9 $1.88 Weighted average diluted shares used 195.6 200.7 196.1 200.9 EPS, amounts and percentages may not sum or recalculate due to rounding.
(1) There were no acquisition and integration-related charges in the three and six months ended April 30, 2026.
The acquisition and integration-related charges in fiscal 2025 were primarily related to the obp Surgical and Cook Medical acquisition and integration expenses. Charges included $3.5 million and $4.8 million related to redundant personnel costs for transitional employees, $1.1 million and $2.4 million of professional services fees, $1.2 million and $2.1 million of inventory fair value step-up amortization, $1.1 million and $1.8 million of facility rationalization costs, and $0.3 million and $0.4 million of other acquisition and integration-related activities in the three and six months ended April 30, 2025. The three months ended April 30, 2025 also included $2.4 million of acquisition-related non-cash cumulative true-up adjustments reflecting changes in compensation.
Charges in this category may include the direct effects of acquisition accounting, such as amortization of inventory fair value step-up, professional services fees, regulatory fees, and items related to integrating acquired businesses, such as redundant personnel costs for transitional employees, acquisition-related non-cash cumulative true up adjustments reflecting changes in compensation, other acquisition-related costs, integration-related professional services, long-lived asset write-offs, manufacturing integration costs, legal entity and facility rationalization, and other integration-related activities.
(2) There were no charges related to the exit of business in the three months ended April 30, 2026. The six months ended April 30, 2026 included $1.7 million of specifically-identified long-lived asset write-offs and $0.1 million of other costs related to product line exits.
There were no exit of business charges in the three and six months ended April 30, 2025.
Charges in this category may include costs related to product line exits such as inventory write-offs, employee severance costs, and specifically-identified long-lived asset write-offs.
(3) Charges represent incremental costs of complying with the new European Union (E.U.) medical device regulations and the E.U. in vitro diagnostic medical device regulation (collectively, the "Medical device regulations") for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be limited to a specific time period.
(4) Charges included $1.1 million and $2.3 million of redundant personnel costs for transitional employees in the three and six months ended April 30, 2026. The six months ended April 30, 2026 also included $0.4 million of employee severance costs and $0.3 million of other business optimization charges.
There were no business optimization charges in the three and six months ended April 30, 2025.
Charges in this category represent costs associated with initiatives to increase efficiency and optimize the cost structure, and may include, among other items, changes to our IT infrastructure and operations, employee severance costs, redundant personnel costs for transitional employees, legal entity and other business reorganizations, and inventories associated with the business optimization activities.
(5) Charges included $4.5 million and $11.2 million related to legal matters and $0.9 million and $1.8 million of gains and losses on minority interest investments in the three and six months ended April 30, 2026. The three months ended April 30, 2026 also included $272.2 million related to litigation expense and associated legal costs.
Charges in the three months ended April 30, 2025 included $16.7 million of gains and losses on minority interest investments, of which $15.7 million was related to loss on disposal of a minority interest investment, and $0.7 million of accretion of interest attributable to acquisition installment payables. Charges in the six months ended April 30, 2025 included $17.9 million of gains and losses on a minority interest investment, $1.4 million of accretion of interest attributable to acquisition installment payables, and $0.6 million legal fees.
Charges in this category may include legal matters, litigation expense, and other items that are not part of ordinary operations. The adjustments to arrive at non-GAAP net income also include gains and losses on minority interest investments and accretion of interest attributable to acquisition installment payables.
(6) In fiscal 2021, the Company transferred its CooperVision intellectual property and goodwill to its UK subsidiary. As a result, we recorded a deferred tax asset equal to approximately $2.0 billion as a one-time tax benefit in accordance with U.S. GAAP in fiscal 2021 as subsequently adjusted for changes in UK tax law. The non-GAAP adjustments reflect the ongoing net deferred tax benefit from tax amortization each period under UK tax law.
Audio Webcast and Conference Call
The Company will host an audio webcast today for the public, investors, analysts and news media to discuss its second quarter results and current corporate developments. The audio webcast will be broadcast live on CooperCompanies' website, www.investor.coopercos.com, at approximately 5:00 PM ET. It will also be available for replay on CooperCompanies' website, www.investor.coopercos.com. Alternatively, you can dial in to the conference call at 800-715-9871; conference ID 6529381.
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women's healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com.
Forward-Looking Statements
This earnings release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to guidance, plans, prospects, goals, strategies, future actions, events or performance and other statements of which are other than statements of historical fact, including our fiscal year 2026 financial guidance, are forward looking. In addition, all statements regarding anticipated growth in our revenues, expected savings from reorganization activities, anticipated effects of any product recalls, anticipated market conditions, planned product launches, restructuring or business transition expectations, regulatory plans, and expected results of operations and integration of any acquisition are forward-looking. To identify these statements look for words like "believes," "outlook," "probable," "expects," "may," "will," "should," "could," "seeks," "intends," "plans," "estimates" or "anticipates" and similar words or phrases. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties.
Among the factors that could cause our actual results and future actions to differ materially from those described in forward-looking statements are: adverse changes in the global or regional general business, political and economic conditions including the impact of continuing uncertainty and instability of certain countries, man-made or natural disasters and pandemic conditions, that could adversely affect our global markets, and the potential adverse economic impact and related uncertainty caused by these items; the impact of international conflicts, including the ongoing conflict in the Middle East, and the global response to international conflicts on the global and local economy, financial markets, energy markets, currency rates and our ability to supply product to, or through, or around, affected countries; our substantial and expanding international operations and the challenges of managing an organization spread throughout multiple countries and complying with a variety of legal, compliance and regulatory requirements; the actual imposition or threats of tariffs, customs duties and fees by the U.S. government and other nations in response and other retaliatory actions, such as trade protection measures, import or export licensing requirements, new or different customs duties, trade embargoes and sanctions and other trade barriers, as well as the impact of the Company’s efforts to mitigate the effects of such tariffs or similar measures; foreign currency exchange rate and interest rate fluctuations including the risk of fluctuations in the value of foreign currencies or interest rates that would decrease our net sales and earnings; our existing and future variable rate indebtedness and associated interest expense is impacted by rate increases, which could adversely affect our financial health or limit our ability to borrow additional funds; changes in tax laws, examinations by tax authorities, and changes in our geographic composition of income; acquisition-related adverse effects including the failure to successfully achieve the anticipated net sales, margins and earnings benefits of acquisitions, integration delays or costs and the requirement to record significant adjustments to the preliminary fair value of assets acquired and liabilities assumed within the measurement period, required regulatory approvals for an acquisition not being obtained or being delayed or subject to conditions that are not anticipated, adverse impacts of changes to accounting controls and reporting procedures, contingent liabilities or indemnification obligations, increased leverage and lack of access to available financing (including financing for the acquisition or refinancing of debt owed by us on a timely basis and on reasonable terms); compliance costs and potential liability in connection with U.S. and foreign laws and health care regulations pertaining to privacy and security of personal information such as the Health Insurance Portability and Accountability Act of 1996 and the California Consumer Privacy Act in the U.S. and the General Data Protection Regulation requirements in Europe, including but not limited to those resulting from data security breaches; a major disruption in the operations of our manufacturing, accounting and financial reporting, research and development, distribution facilities or raw material supply chain due to challenges associated with integration of acquisitions, man-made or natural disasters, pandemic conditions, cybersecurity incidents or other causes; a major disruption in the operations of our manufacturing, accounting and financial reporting, research and development or distribution facilities due to the failure to perform by third-party vendors, including cloud computing providers or other technological problems, including any related to our information systems maintenance, enhancements or new system deployments, integrations or upgrades; a successful cybersecurity attack which could interrupt or disrupt our information technology systems, or those of our third-party service providers, or cause the loss of confidential or protected data; market consolidation of large customers globally through mergers or acquisitions resulting in a larger proportion or concentration of our business being derived from fewer customers; disruptions in supplies of raw materials, particularly components used to manufacture our silicone hydrogel lenses; new U.S. and foreign government laws and regulations, and changes in existing laws, regulations and enforcement guidance, which affect areas of our operations including, but not limited to, those affecting the health care industry, including the contact lens industry specifically and the medical device or pharmaceutical industries generally, including but not limited to the EU Medical Devices Regulation (MDR) and the EU In Vitro Diagnostic Medical Devices Regulation; legal costs, insurance expenses, settlement costs and the risk of an adverse decision, prohibitive injunction or settlement related to product liability, patent infringement, contractual disputes, or other litigation; limitations on sales following product introductions due to poor market acceptance; new competitors, product innovations or technologies, including but not limited to, technological advances by competitors, new products and patents attained by competitors, and competitors' expansion through acquisitions; reduced sales, loss of customers, reputational harm and costs and expenses, including from claims and litigation related to product recalls and warning letters; failure to receive, or delays in receiving, regulatory approvals or certifications for products; failure of our customers and end users to obtain adequate coverage and reimbursement from third-party payers for our products and services; the requirement to provide for a significant liability or to write off, or accelerate depreciation on, a significant asset, including goodwill, other intangible assets and idle manufacturing facilities and equipment; the success of our research and development activities and other start-up projects; dilution to earnings per share from acquisitions or issuing stock; impact and costs incurred from changes in accounting standards and policies; risks related to environmental laws and requirements applicable to our facilities, products or manufacturing processes, including evolving regulations regarding the use of hazardous substances or chemicals in our products; risks related to environmental, social and corporate governance issues, including those related to regulatory and disclosure requirements, climate change and sustainability; and other events described in our United States Securities and Exchange Commission filings, including the “Business”, “Risk Factors” and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections in the Company’s Annual Report on Form 10-K for the fiscal year ended October 31, 2025, as such Risk Factors may be updated in annual and quarterly filings.
We caution investors that forward-looking statements reflect our analysis only on their stated date. We disclaim any obligation to update or revise them except as required by law.
Contact:
Kim Duncan
Vice President, Investor Relations and Risk Management
925-460-3663 [email protected]
THE COOPER COMPANIES, INC. AND SUBSIDIARIESConsolidated Condensed Balance Sheets
(In millions)
(Unaudited) April 30, 2026 October 31, 2025ASSETSCurrent assets: Cash and cash equivalents$138.8 $110.6Trade receivables, net 809.2 829.0Inventories 896.4 846.0Prepaid expense and other current assets 455.4 320.8Total current assets 2,299.8 2,106.4Property, plant and equipment, net 2,132.2 2,082.0Goodwill 3,888.5 3,853.4Other intangibles, net 1,494.3 1,586.3Deferred tax assets 1,994.7 2,077.5Other assets 672.8 689.2Total assets$12,482.3 $12,394.8 LIABILITIES AND STOCKHOLDERS’ EQUITYCurrent liabilities: Short-term debt$598.9 $47.8Accounts Payable 233.3 300.4Employee compensation and benefits 165.9 210.6Deferred revenue 127.9 127.9Accrued litigation liability 324.8 0.7Other current liabilities 353.9 425.4Total current liabilities 1,804.7 1,112.8Long-term debt 1,861.3 2,457.5Deferred tax liabilities 96.4 93.3Long-term tax payable 5.6 7.5Deferred revenue 208.8 201.8Other liabilities 266.4 282.8Total liabilities 4,243.2 4,155.7Stockholders’ equity 8,239.1 8,239.1Total liabilities and stockholders' equity$12,482.3 $12,394.8 THE COOPER COMPANIES, INC. AND SUBSIDIARIESConsolidated Condensed Statements of Income (Loss)
(In millions, except per share amounts)
(Unaudited) Three Months Ended April 30, Six Months Ended April 30, 2026 2025
2026 2025
Net sales$1,081.5 $1,002.3 $2,105.6 $1,967.0Cost of sales 346.1 323.2 675.0 627.7Gross profit 735.4 679.1 1,430.6 1,339.3Selling, general and administrative expense 676.2 399.0 1,066.4 786.9Research and development expense 42.5 45.5 86.8 86.2Amortization of intangibles 47.7 49.8 95.6 99.4Operating income (loss) (31.0) 184.8 181.8 366.8Interest expense 20.9 24.2 43.3 50.2Other (income) expense, net (3.5) 16.1 (5.3) 18.8Income (loss) before income taxes (48.4) 144.5 143.8 297.8Provision for income taxes 29.5 56.8 90.9 105.8Net income (loss)$(77.9) $87.7 $52.9 $192.0 Earnings (loss) per share - diluted$(0.40) $0.44 $0.27 $0.96 Number of shares used to compute diluted earnings (loss) per share 195.0 200.7 196.1 200.9 EPS, amounts and percentages may not sum or recalculate due to rounding.
THE COOPER COMPANIES, INC. AND SUBSIDIARIESGAAP to Non-GAAP Reconciliation
Constant Currency Revenue Growth and Organic Revenue Growth Net Sales % change y/y (In millions) Reported
Currency Impact
Constant Currency
Acquisitions and Divestitures
Organic
2Q26 CooperVision$723.5 8% (4)% 4% —% 4%CooperSurgical 358.0 8% (2)% 6% —% 6%Total$1,081.5 8% (3)% 5% —% 5%
The Cooper Companies (COO - Free Report) came out with quarterly earnings of $1.21 per share, beating the Zacks Consensus Estimate of $1.1 per share. This compares to earnings of $0.96 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +9.67%. A quarter ago, it was expected that this surgical and contact lens products maker would post earnings of $1.03 per share when it actually produced earnings of $1.1, delivering a surprise of +6.8%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
The Cooper Companies, which belongs to the Zacks Medical - Dental Supplies industry, posted revenues of $1.08 billion for the quarter ended April 2026, surpassing the Zacks Consensus Estimate by 2.57%. This compares to year-ago revenues of $1 billion. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
The Cooper Companies shares have lost about 26.4% since the beginning of the year versus the S&P 500's gain of 10.4%.
What's Next for The Cooper Companies?While The Cooper Companies has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for The Cooper Companies was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.18 on $1.12 billion in revenues for the coming quarter and $4.62 on $4.32 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Dental Supplies is currently in the top 26% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the broader Zacks Medical sector, Icon PLC (ICLR - Free Report) , is yet to report results for the quarter ended March 2026.
This contract research organization is expected to post quarterly earnings of $2.86 per share in its upcoming report, which represents a year-over-year change of -10.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Icon PLC's revenues are expected to be $2 billion, down 0% from the year-ago quarter.
Have you evaluated the performance of The Cooper Companies' (COO - Free Report) international operations for the quarter ending April 2026? Given the extensive global presence of this surgical and contact lens products maker, analyzing the patterns in international revenues is crucial for understanding its financial strength and potential for growth.
The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its financial success and growth path. It has become essential for investors to comprehend how much a company relies on these foreign markets, as this understanding reveals the firm's potential for consistent earnings, its capacity to harness different economic cycles, and its overall growth prospects.
Being present in foreign markets serves as protection against local economic declines and helps benefit from more rapidly expanding economies. Yet, such expansion also introduces challenges related to currency fluctuations, geopolitical uncertainties and varied market behaviors.
While analyzing COO's performance for the last quarter, we found some intriguing trends in revenues from its overseas segments that Wall Street analysts commonly model and monitor.
The company's total revenue for the quarter stood at $1.08 billion, increasing 7.9% year over year. Now, let's delve into COO's international revenue breakdown to gain insights into the significance of its operations beyond home turf.
A Look into COO's International Revenue StreamsOf the total revenue, $289.7 million came from EMEA during the last fiscal quarter, accounting for 26.8%. This represented a surprise of +5.18% as analysts had expected the region to contribute $275.45 million to the total revenue. In comparison, the region contributed $282.3 million, or 27.6%, and $248.6 million, or 24.8%, to total revenue in the previous and year-ago quarters, respectively.
Asia Pacific generated $130.6 million in revenues for the company in the last quarter, constituting 12.1% of the total. This represented a surprise of -0.17% compared to the $130.83 million projected by Wall Street analysts. Comparatively, in the previous quarter, Asia Pacific accounted for $123.8 million (12.1%), and in the year-ago quarter, it contributed $138.6 million (13.8%) to the total revenue.
International Revenue PredictionsThe current fiscal quarter's total revenue for The Cooper Companies, as projected by Wall Street analysts, is expected to reach $1.12 billion, reflecting an increase of 5.6% from the same quarter last year. The breakdown of this revenue by foreign region is as follows: EMEA is anticipated to contribute 27.3% or $305.46 million, and Asia Pacific 12.8% or $143.73 million.
For the entire year, the company's total revenue is forecasted to be $4.31 billion, which is an improvement of 5.4% from the previous year. The revenue contributions from different regions are expected as follows: EMEA will contribute 26.6% ($1.15 billion), and Asia Pacific 12.8% ($552.45 million) to the total revenue.
Key TakeawaysThe dependency of The Cooper Companies on global markets for its revenues presents a mix of potential gains and hazards. Thus, monitoring the trends in its overseas revenues can be a key indicator for predicting the firm's future performance.
In a world where international interdependencies and geopolitical conflicts are ever-increasing, Wall Street analysts closely monitor these trends for companies having international presence to adjust their earnings forecasts. Of course, there are several other factors, including a company's standing within its home borders, that influence analysts' earnings forecasts.
We at Zacks strongly focus on the dynamic earnings forecast of companies, given that empirical studies have demonstrated its potent impact on the immediate price movement of stocks. Invariably, there's a positive relationship -- upward earnings predictions often result in an increase in stock prices.
The Zacks Rank, our proprietary stock rating mechanism, demonstrates a notable performance history confirmed through external audits. It effectively utilizes the power of earnings estimate revisions to act as a predictor of a stock's price performance in the near term.
The Cooper Companies, bearing a Zacks Rank #3 (Hold), is expected to mirror the broader market's movements in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Assessing The Cooper Companies' Stock Price Movement in Recent TimesOver the preceding four weeks, the stock's value has appreciated by 12.2%, against an upturn of 1.9% in the Zacks S&P 500 composite. In parallel, the Zacks Medical sector, which counts The Cooper Companies among its entities, has appreciated by 3.1%. Over the past three months, the company's shares have seen a decline of 3.7% versus the S&P 500's 8.5% increase. The sector overall has witnessed a decline of 3.3% over the same period.
The Cooper Companies, Inc. remains a Hold as valuation nears attractive levels but litigation risk and mixed profitability warrant caution. Revenue growth is robust, particularly in the CooperVision segment, with strong performance in EMEA and the Americas offsetting Asia Pacific softness. Litigation charges from embryo culture media recalls have materially impacted reported profitability, but are not expected to alter COO's long-term outlook.
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
#1 (Strong Buy) stocks have produced an unmatched +23.7% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: The Cooper Companies (COO - Free Report) The Cooper Companies is a global medical device company operating through two main segments: CooperVision (CVI) and CooperSurgical (CSI). CVI focuses on contact lenses, with a strong presence in daily silicone hydrogel lenses, torics, multifocals, and myopia management. Its flagship MyDay franchise, including MyDay Energys and toric/multifocal expansions, continues to capture premium share, while MiSight addresses the growing myopia epidemic. CSI provides products and services in fertility and women’s health, offering in-vitro fertilization (IVF) solutions, contraceptives such as Paragard, and office/surgical devices.
COO is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
Additionally, the company could be a top pick for growth investors. COO has a Growth Style Score of B, forecasting year-over-year earnings growth of 12.4% for the current fiscal year.
Four analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.01 to $4.63 per share. COO also boasts an average earnings surprise of +5.8%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, COO should be on investors' short list.
